Congressional spending plan: What’s in it for healthcare, and what isn’t
Chief Healthcare Executive December 21, 2024
A Biotech Startup’s Quest to Relieve Pulmonary Mucus Obstruction for Respiratory Care
MedCity News December 4, 2024
In response to emailed questions, the founders of MucoLife Therapeutics shared their company’s approach, which is designed to help people with COPD, cystic fibrosis, asthma, and pulmonary fibrosis.
MucoLife Therapeutics, an alumnus of the Health Wildcatters accelerator, develops patented, innovative mucus-dissolving therapies specifically targeting pulmonary mucus obstruction. In response to emailed questions, the founders shared their company’s approach, which is designed to help people with obstructive respiratory conditions, such as COPD, cystic fibrosis, asthma, and pulmonary fibrosis.
Why did you start this company?
MucoLife Therapeutics was born in 2024 from the visionary efforts of Thaher Pelaseyed and Gunnar Hansson, two trailblazing scientists from the Mucin Biology Groups (MBG) at the University of Gothenburg, Sweden. Renowned as a global leader in...
Today's Sponsors
Today's Sponsor